The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Allergan Aesthetics’ Botox (onabotulinumtoxinA) to treat platysma bands.
The MHRA approval allows for the temporary improvement in the appearance of moderate to severe platysma prominence. The condition must be observed at maximum muscle contraction and have a significant psychological impact to qualify for treatment. According to the company, this approval marks the first non-surgical neurotoxin treatment in the UK specifically authorised for this indication.
Djamshid Ghavami, UK&I general manager at Allergan Aesthetics, an AbbVie company, commented, “At Allergan Aesthetics, our purpose is to empower confidence, creating the products and technologies that drive the advancement of medical aesthetics. This new indication is a testament to this purpose. Evolving what’s possible in aesthetics and meeting an unmet need for adult patients by introducing the first non-surgical neurotoxin treatment option for platysma bands in the neck and lower face area.”
Aesthetic practitioner Dr Nestor Demosthenous commented, “This is an extremely important time with the approval of moderate to severe platysma prominence treatment with Botox. This allows us to effectively treat a new concern non-surgically, which patients have been wanting for years, backed by strong scientific evidence and MHRA approval.”
